Dyadic International (DYAI) IAccess Alpha Virtual MicroCap Conference summary

Strategic direction and platform evolution

• Transitioned from R&D and grant-based revenues to commercial applications in life sciences, food nutrition, and bio-industrial markets, focusing on scalable, animal-free recombinant proteins.

• Developed two core microbial platforms, C1 and Dapibus, optimized for speed, productivity, and cost, targeting different market segments and margins.

• Shifted focus to non-therapeutic products, enabling faster commercialization and lower regulatory hurdles, with a 12–18 month timeline from proof of concept to revenue.

• Adopted a three-pillar monetization strategy: direct product sales, licensing/branding, and enabling partners to build their own products using proprietary technology.

• Maintains legacy R&D programs in therapeutics, supported by external funding, to enhance platform validation and visibility.

Commercialization and product pipeline

• Multiple product launches planned from late 2025 through 2027, including human albumin, transferrin, DNase I, and bovine growth factors, with initial revenues already realized.

• Partnerships with Proliant, Brig Bio, Enzymes, and Fermbox Bio drive commercialization in cell culture media, non-animal dairy, and bio-industrial enzymes.

• Entered Asia-Pacific markets via Intralink partnership, expanding reach in rapidly growing cell and gene therapy segments.

• Food nutrition focus includes non-animal dairy proteins like alpha-lactalbumin and lactoferrin, targeting infant, sports, and medical nutrition.

• Bio-industrial segment targets cellulosic enzymes for biofuels and biomass processing, with initial revenues expected in early 2026.

Revenue outlook and financial targets

• Anticipates meaningful revenue growth beginning in Q1–Q2 2026, with layered revenues from direct sales, partnerships, and licensing.

• Customer pipeline spans cell culture media, non-animal dairy, and industrial applications, with multiple OEM and direct sales agreements in place.

• Operating leverage expected due to rapid, cost-effective strain development; typical product development costs are around $200,000.

• Cash flow positive expected at approximately $12 million annual revenue run rate, with higher margins in life sciences than in food or industrial segments.

• Commercial strategy supported by a veteran leadership team and recent organizational rebranding to align with growth objectives.